You are here: Industry Insights > biologics

News List

Inauguration of the New Richter BioLogics cGMP Facility for the Manufacture of Biopharmaceuticals for the Global Market PharmaSources
October 14, 2024
Richter BioLogics GmbH & Co KG, the microbial biologics affiliate of Gedeon Richter Plc. celebrated the opening of its new cutting-edge biopharmaceutical cGMP facility in Bovenau .
Research Progress on the Application of Biologics in Pediatric Asthma Xiaomichong
July 19, 2024
Asthma is a heterogeneous and complex chronic disease. Children with severe asthma often experience acute exacerbations, ultimately leading to impaired lung function and poor quality of life.
Celonic Inaugurates “Next Generation” Biologics Development Center (BDC) and Pilot Plant in Basel, Switzerland Biotech Newswire
June 24, 2024
The Celonic Group, a Swiss Based Quality Biologics Contract Development and Manufacturing Organization (CDMO) today opened its “Next Generation” Biologics Development Center and Pilot Plant in Basel, Switzerland.
Research Progress on the Application of Biologics in Childhood Asthma. Xiaomichong
October 30, 2023
Asthma is a heterogeneous, complex chronic disease. Children with severe asthma often experience acute exacerbations, leading to impaired lung function and poor quality of life.
Polpharma Biologics Announces Approval of Europe’s First and Only Biosimilar for Multiple Sclerosis - Tyruko® (Natalizumab) B3C newswire
November 06, 2023
Polpharma Biologics, today announced that the European Commission (EC) has approved Tyruko® (natalizumab) as the first and only biosimilar for relapsing forms of multiple sclerosis (MS) in Europe.
Polpharma Biologics Announces FDA Approval of Tyruko® - First And Only Approved Biosimilar to Tysabri®* for Relapsing Forms of Multiple Sclerosis PharmaSources
August 28, 2023
On August 25, 2023,Polpharma Biologics announced today that the U.S. Food and Drug Administration (FDA) is the first regulatory body worldwide to approve the use of Tyruko®.
Polpharma Biologics Announces First-of-a-Kind Multiple Sclerosis Biosimilar Natalizumab Receives Positive CHMP Opinion PharmaSources
July 24, 2023
Polpharma biologics announces first-of-a-kind multiple sclerosis biosimilar natalizumab receives positive CHMP opinion.
AGC Biologics Supports Omicron-based Vaccine Candidate Manufacturing contractpharma
February 09, 2022
Global CDMO’s Heidelberg facility supplies more pDNA material to help address growing needs.
I-Mab Announces Partnership Agreement to Localize Manufacturing and Accelerate Commercialization of Innovative Biologics Drugs prnasia
January 29, 2022
I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics...
Samsung Biologics to buy out Biogen's stake in Samsung Bioepis CPhIonline
January 29, 2022
Samsung Biologics has reached an agreement for the buyout of Biogen’s stake in the Samsung Bioepis joint venture for USD $2.3 billion.